WWOX, the common chromosomal fragile site, FRA16D, cancer gene

Cytogenetic and Genome Research

Volumn 100, Issue 1-4, 2003, Pages 101-110

  Ludes Meyers, J H ^a   Bednarek, A K ^b   Popescu, N C ^c   Bedford, M ^a   Aldaz, C M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WW DOMAIN CONTAINING OXIDOREDUCTASE;

ALLELE; ANEUPLOIDY; CARCINOGENESIS; CHROMOSOME 16; CHROMOSOME DELETION; CHROMOSOME FRAGILE SITE; CHROMOSOME LOSS; EXON; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE INACTIVATION; GENE LOCATION; GENE MUTATION; GENE STRUCTURE; GOLGI COMPLEX; HOMOZYGOSITY; HUMAN; KARYOTYPE; MITOTIC RECOMBINATION; MOLECULAR CLONING; MONOSOMY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; REVIEW; RNA SPLICING; SOLID TUMOR; TUMOR SUPPRESSOR GENE;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; BLOTTING, WESTERN; BREAST NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; CHROMOSOME FRAGILE SITES; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 16; CLONING, MOLECULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GOLGI APPARATUS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LOSS OF HETEROZYGOSITY; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; REVIEW LITERATURE; RNA, MESSENGER;

EID: 0344100087     PISSN: 14248581     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072844     Document Type: Review

References (56)

1. Aldaz CM, Chen T, Sahin A, Cunningham J, Bondy M: Comparative allelotype of in situ and invasive human breast cancer: high frequency of microsatellite instability in lobular breast carcinomas. Cancer Res 55:3976-3981 (1995).
2. Bednarek AK, Keck-Waggoner CL, Daniel RL, Laflin KJ, Bergsagel PL, Kiguchi K, Brenner AJ, Aldaz CM: WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res 61:8068-8073 (2001).
3. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM: WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3→q24.1, a region frequently affected in breast cancer. Cancer Res 60:2140-2145 (2000).
4. Berx G, Cleton-Jansen A, Nollet F, de Leeuw W, van de Vijver M, Cornelisse C, van Roy F E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 14:6107-6115 (1995).
5. Brenner AJ, Aldaz CM: Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. Cancer Res 55:2892-2895 (1995).
6. Buerger H, Otterbach F, Simon R, Poremba C, Diallo R, Decker T, Riethdorf L, Brinkschmidt C, Dockhorn-Dworniczak B, Boecker W: Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol 187:396-402 (1999).
7. Chang NS, Pratt N, Heath J, Schultz L, Sleve D, Carey GB, Zevotek N: Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J biol Chem 276:3361-3370 (2001).
8. Charpentier A, Aldaz CM: The molecular basis of breast carcinogenesis, in Coleman WB, Tsongalis GJ (eds): Molecular Basis of Human Cancer: Genomic Instability and Molecular Mutation in Neoplastic Transformation, pp 347-363 (Humana Press, Totowa 2002).
9. Chen T, Sahin A, Aldaz C: Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: refining a putative tumor suppressor gene region. Cancer Res 56:5605-5609 (1996).
10. Cher ML, Ito T, Weidner N, Carroll PR, Jensen RH: Mapping of regions of physical deletion on chromosome 16q in prostate cancer cells by fluorescence in situ hybridization (FISH). J Urol 153:249-254 (1995).
11. Chesi M, Bergsagel PL, Shonukan OO, Martelli ML, Brents LA, Chen T, Schrock E, Ried T, Kuehl WM: Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 91: 4457-4463 (1998).
12. Cleton-Jansen A, Moerland E, Kuipers-Dijkshoorn N, Callen D, Sutherland G, Hansen B, Devilee P, Cornelisse C: At least two different regions are involved in allelic imbalance on chromosome arm 16q in breast cancer. Genes Chrom Cancer 9:101-107 (1994).
13. Crawford J, Ianzano L, Savino M, Whitmore S, Cleton-Jansen AM, Settasatian C, d'apolito M, Seshadri R, Pronk JC, Auerbach AD, Verlander PC, Mathew CG, Tipping AJ, Doggett NA, Zelante L, Callen DF, Savoia A: The PISSLRE gene: structure, exon skipping, and exclusion as tumor suppressor in breast cancer. Genomics 56:90-97 (1999).
14. Croce CM, Sozzi G, Huebner K: Role of FHIT in human cancer. J Clin Oncol 17:1618-1624 (1999).
15. Driouch K, Prydz H, Monese R, Johansen H, Lidereau R, Frengen E: Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oncogene 21:1832-1840 (2002).
16. Dutrillaux B, Gerbault-Seureau M, Zafrani B: Characterization of chromosomal anomalies in human breast cancer. A comparison of 30 paradiploid cases with few chromosome changes. Cancer Genet Cytogenet 49:203-217 (1990).
17. Elo JP, Harkonen P, Kyllonen AP, Lukkarinen O, Vihko P: Three independently deleted regions at chromosome arm 16q in human prostate cancer: allelic loss at 16q24.1→q24.2 is associated with aggressive behaviour of the disease, recurrent growth, poor differentiation of the tumour and poor prognosis for the patient. Br J Cancer 79:156-160 (1999).
18. Fujii H, Szumel R, Marsh C, Zhou W, Gabrielson E: Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast. Cancer Res 56:5260-5265 (1996).
19. Futreal PA, Cochran C, Rosenthal J, Miki Y, Swenson J, Hobbs M, Bennett LM, Haugen-Strano A, Marks J, Barrett JC, et al: Isolation of a diverged homeobox gene, MOX1, from the BRCA1 region on 17q21 by solution hybrid capture. Hum molec Genet 3:1359-1364 (1994).
20. Gabrielli F, Donadel G, Bensi G, Heguy A, Melli M: A nuclear protein, synthesized in growth-arrested human hepatoblastoma cells, is a novel member of the short-chain alcohol dehydrogenase family. Eur J Biochem 232:473-477 (1995).
21. Glover TW, Berger C, Coyle J, Echo B: DNA polymerase alpha inhibition by aphidicolin induces gap and breaks at common fragile sites in human chromosomes. Hum Genet 67:136-142 (1984).
22. Gong G, DeVries S, Chew KL, Cha I, Ljung BM, Waldman FM: Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization. Clin Cancer Res 7:2410-2414 (2001).
23. Gupta PK, Sahota A, Boyadjiev SA, Bye S, Shao C, O'Neill JP, Hunter TC, Albertini RJ, Stambrook PJ, Tischfield JA: High frequency in vivo loss of heterozygosity is primarily a consequence of mitotic recombination. Cancer Res 57:1188-1193 (1997).
24. Huebner K, Croce CM: FRA3B and other common fragile sites: the weakest links. Nature Rev Cancer 1:214-221 (2001).
25. Iwabuchi H, Sakamoto M, Sakunaga H, Ma YY, Carcangiu ML, Pinkel D, Yang-Feng TL, Gray JW: Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res 55:6172-6180 (1995).
26. Kallberg Y, Oppermann U, Jornvall H, Persson B: Short-chain dehydrogenase/reductase (SDR) relationships: A large family with eight clusters common to human, animal, and plant genomes. Protein Sci 11:636-641 (2002).
27. Kawakami M, Staub J, Cliby W, Hartmann L, Smith DI, Shridhar V: Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer. Int J Oncol 15:715-720 (1999).
28. Krummel KA, Denison SR, Calhoun E, Phillips LA, Smith DI: The common fragile site FRA16D and its associated gene WWOX are highly conserved in the mouse at Fra8E1. Genes Chrom Cancer 34:154-167 (2002).
29. Krummel KA, Roberts LR, Kawakami M, Glover TW, Smith DI: The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations. Genomics 69:37-46 (2000).
30. Kuroki T, Trapasso F, Shiraishi T, Alder H, Mimori K, Mori M, Croce CM: Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res 62:2258-2260 (2002).
31. Lakhani SR, Collins N, Sloane JP, Stratton MR: Loss of heterozygosity in lobular carcinoma in situ of the breast. J clin Pathol: Mol Pathol 48:M74-M78 (1995).
32. Le Beau MM, Drabkin H, Glover TW, Gemmill R, Rassool FV, McKeithan TW, Smith DI: An FHIT tumor suppressor gene? Genes Chrom Cancer 21:281-289 (1998).
33. Li C, Berx G, Larsson C, Auer G, Aspenblad U, Pan Y, Sundelin B, Ekman P, Nordenskjold M, van Roy F, Bergerheim US: Distinct deleted regions on chromosome segment 16q23→q24 associated with metastases in prostate cancer. Genes Chrom Cancer 24:175-182 (1999).
34. Lin B, White JT, Ferguson C, Wang S, Vessella R, Bumgarner R, True LD, Hood L, Nelson PS: Prostate short-chain dehydrogenase reductase 1 (PSDR1): a new member of the short-chain steroid dehydrogenase/reductase family highly expressed in normal and neoplastic prostate epithelium. Cancer Res 61:1611-1618 (2001).
35. Lu YJ, Osin P, Lakhani SR, Di Palma S, Gusterson BA, Shipley JM: Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. Cancer Res 58:4721-4727 (1998).
36. Mangelsdorf M, Ried K, Woollatt E, Dayan S, Eyre H, Finnis M, Hobson L, Nancarrow J, Venter D, Baker E, Richards RI: Chromosomal fragile site FRA16D and DNA instability in cancer. Cancer Res 60:1683-1689 (2000).
37. Nishida N, Fukuda Y, Kokuryu H, Sadamoto T, Isowa G, Honda K, Yamaoka Y, Ikenaga M, Imura H, Ishizaki K: Accumulation of allelic loss on arms of chromosomes 13q, 16q and 17p in the advanced stages of human hepatocellular carcinoma. Int J Cancer 51:862-868 (1992).
38. O'Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC: Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J natl Cancer Inst 90:697-703 (1998).
39. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, et al: The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84:587-597 (1996).
40. Page DL, Dupont WD: Anatomic markers of human premalignancy and risk of breast cancer. Cancer 66:1326-1335 (1990).
41. Paige AJ, Taylor KJ, Stewart A, Sgouros JG, Gabra H, Sellar GC, Smyth JF, Porteous DJ, Watson JE: A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D. Cancer Res 60:1690-1697 (2000).
42. Paige AJ, Taylor KJ, Taylor C, Hillier SG, Farrington S, Scott D, Porteous DJ, Smyth JF, Gabra H, Watson JE: WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc natl Acad Sci, USA 98:11417-11422 (2001).
43. Pandis N, Heim S, Bardi G, Idvall I, Mandahl N, Mitelman F: Whole-arm t(1;16) and i(1q) as sole anomalies identify gain of 1q as a primary chromosomal abnormality in breast cancer. Genes Chrom Cancer 5:235-238 (1992).
44. Radford D, Fair K, Phillips N, Ritter J, Steinbrueck T, Holt M, Donis-Keller H: Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. Cancer Res 55:3399-3405 (1995).
45. Richards RI: Fragile and unstable chromosomes in cancer: causes and consequences. Trends Genet 17:339-345 (2001).
46. Ried K, Finnis M, Hobson L, Mangelsdorf M, Dayan S, Nancarrow JK, Woollatt E, Kremmidiotis G, Gardner A, Venter D, Baker E, Richards RI: Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum molec Genet 9:1651-1663 (2000).
47. Rimokh R, Gadoux M, Bertheas MF, Berger F, Garos Germain D, Magaud JP FVT-1, a novel human transcription unit affected by variant translocation t(2;18)(p11;q21) of follicular lymphoma. Blood 81:136-142 (1993).
48. Savino M, d'Apolito M, Centra M, van Beerendonk HM, Cleton-Jansen AM, Whitmore SA, Crawford J, Callen DF, Zelante L, Savoia A: Characterization of copine VII, a new member of the copine family, and its exclusion as a candidate in sporadic breast cancers with loss of heterozygosity at 16q24.3. Genomics 61:219-226 (1999).
49. Shiraishi T, Druck T, Mimori K, Flomenberg J, Berk L, Alder H, Miller W, Huebner K, Croce CM: Sequence conservation at human and mouse orthologous common fragile regions, FRA3B/FHIT and Fra14A2/Fhit. Proc natl Acad Sci, USA 98:5722-5727 (2001).
50. Skotnicka-Klonowicz G, Rieske P, Bartkowiak J, Szymik-Kantorowicz S, Daszkiewicz P, Debiec-Rychter M: 16q heterozygosity loss in Wilms' tumour in children and its clinical importance. Eur J Surg Oncol 26:61-66 (2000).
51. Smith DI, Huang H, Wang L: Common fragile sites and cancer (Review). Int J Oncol 12:187-196 (1998).
52. Sudol M, Hunter T: NeW wrinkles for an old domain. Cell 103:1001-1004 (2000).
53. Sutherland GR, Baker E, Richards RI: Fragile sites still breaking. Trends Genet 14:501-506 (1998).
54. Suzuki H, Komiya A, Emi M, Kuramochi H, Shiraishi T, Yatani R, Shimazaki J: Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers. Genes Chrom Cancer 17:225-233 (1996).
55. Tapon N, Harvey KF, Bell DW, Wahrer DC, Schiripo TA, Haber DA, Hariharan IK: salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell 110:467-478 (2002).
56. Yunis JJ, Soreng AL: Constitutive fragile sites and cancer. Science 226:1199-1204 (1984).